A detailed history of Morgan Stanley transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 884 shares of INDP stock, worth $1,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares
884
Previous 884 -0.0%
Holding current value
$1,034
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$1.75 - $2.75 $253 - $398
-145 Reduced 14.09%
884 $1,000
Q3 2023

Nov 15, 2023

BUY
$1.75 - $3.95 $350 - $790
200 Added 24.13%
1,029 $2,000
Q1 2023

May 15, 2023

BUY
$1.51 - $1.9 $453 - $570
300 Added 56.71%
829 $1,000
Q4 2022

Feb 14, 2023

SELL
$1.37 - $2.19 $17 - $28
-13 Reduced 2.4%
529 $0
Q2 2022

Oct 27, 2022

SELL
$1.94 - $4.02 $9 - $20
-5 Reduced 0.91%
542 $1,000
Q2 2022

Aug 15, 2022

SELL
$1.94 - $4.02 $9 - $20
-5 Reduced 0.91%
542 $1,000
Q1 2022

Oct 27, 2022

BUY
$3.19 - $6.17 $15 - $30
5 Added 0.92%
547 $2,000
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.93 $46 - $71
-9 Reduced 1.62%
547 $3,000
Q3 2021

Nov 15, 2021

BUY
$7.07 - $14.84 $3,930 - $8,251
556 New
556 $4,000

Others Institutions Holding INDP

About Indaptus Therapeutics, Inc.


  • Ticker INDP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,258,600
  • Market Cap $9.66M
  • Description
  • Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...
More about INDP
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.